Evidence map›Paper›PMID 35321556›Full record

ArticleJournal of clinical microbiology2022

Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.

Jeremy Ratcliff, Farah Al-Beidh, Sagida Bibi, David Bonsall, Sue Ann Costa Clemens, Lise Estcourt, Amy Evans, Matthew Fish, Pedro M Folegatti, Anthony C Gordon and 19 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 7 institutions in 3 countries.

Jeremy RatcliffPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0001-6522-138X
Farah Al-BeidhImperial College London, London, United Kingdom.
Sagida BibiOxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
David BonsallBig Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0003-2187-0550
Sue Ann Costa ClemensOxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Lise EstcourtHaematology Theme, Radcliffe Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Amy EvansClinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom.
Matthew FishSchool of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Pedro M FolegattiCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Anthony C GordonImperial College London, London, United Kingdom.
Cecilia JayPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0003-2387-9225
Aislinn JenningsSchool of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Emma LaingClinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom.
Teresa LambeCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
George MacIntyre-CockettBig Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
David MenonUniversity Division of Anaesthesia, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Paul R MounceyIntensive Care National Audit and Research Centre, London, United Kingdom.
Dung NguyenPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Maheshi N RamasamyOxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
David J RobertsHaematology Theme, Radcliffe Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Kathryn M RowanIntensive Care National Audit and Research Centre, London, United Kingdom.
Jennifer RynneSchool of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Manu Shankar-HariSchool of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.ORCID 0000-0002-5338-2538
Sarah WilliamsPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Heli HarvalaMicrobiology Services, NHS Blood and Transport, London, United Kingdom.
Tanya GolubchikBig Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0003-2765-9828
Peter SimmondsPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0002-7964-4700
AMPHEUS Project, REMAP-CAP Immunoglobulin Domain UK Investigators, and Oxford COVID-19 Vaccine Trial Group
University of Oxford · GBNHS Blood and Transplant · GBSt Thomas' Hospital · GBIntensive Care National Audit & Research Centre · GBSt Mary's Hospital · GBUniversity of Cambridge · GBUniversity of Siena · IT

Funding

CIHR 158584CIHR 447335Wellcome Trust
6 · The paper itself

Abstract

Tools to detect SARS-CoV-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality. To this aim, an allele-specific probe PCR (ASP-PCR) targeting lineage-specific single nucleotide polymorphisms (SNPs) was developed and used to screen 1,082 samples from two clinical trials in the United Kingdom and Brazil. Probit regression models were developed to compare ASP-PCR performance against 1,771 NGS results for the same cohorts. Individual SNPs were shown to readily identify specific variants of concern. ASP-PCR was shown to discriminate SARS-CoV-2 lineages with a higher likelihood than NGS over a wide range of viral loads. The comparative advantage for ASP-PCR over NGS was most pronounced in samples with cycle threshold (

Indexed as

COVID-19SARS-CoV-2AllelesHumansPolymerase Chain Reactionallele-specific probe PCRdiagnosticsnext-generation sequencingSARS-CoV-2variant identificationvariants of concern

Identifiers

PMID35321556
PMCPMC9020347
OpenAlexW4220922945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.